Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

results of the second trial are pending, the current intention is not to pursue a regulatory filing for this indication for MMX mesalamine.

Lisdexamfetamine dimesylate ("LDX") (currently marketed as VYVANSE in the US for the treatment of ADHD) for the treatment of Binge Eating Disorder ("BED")

  • Today, Shire announced Phase 2 results from an efficacy and safety clinical study of LDX for the treatment of BED. In this study, in which the pre-defined primary end point was met, treatment of adults with LDX resulted in a statistically significant reduction in binge eating behaviour and increased remission rates from binge eating compared to placebo. There is currently no approved pharmacologic treatment for patients struggling with BED, the most common eating disorder.

FIRST QUARTER AND RECENT BUSINESS DEVELOPMENT ACTIVITY

Since the beginning of the year we have added to our pipeline through the following transactions:


Acquisition of FerroKin Biosciences, Inc. ("FerroKin")

  • On April 2, 2012 Shire completed the acquisition of FerroKin and with it SPD 602 (formally referred to as FBS0701), FerroKin's iron chelator treatment in Phase 2 development. SPD 602 serves a chronic patient need for treatment of iron overload following numerous blood transfusions. Together with our collaboration with Sangamo Biosciences Inc. ("Sangamo"), the acquisition of FerroKin represents a strategic step in building Shire's hematology business, which already includes XAGRID® and a growing development pipeline, including SPD 535. Cash consideration paid on closing amounted to $94.5 million. Further contingent cash consideration of up to $225 million may be payable by Shire in future periods, dependent upon the achievement of certain clinical development, regulatory and net sales milestones.

Acquisition of certain assets
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... VILLAGE, Nev. , June 29, 2015  PDL ... it has entered into a credit agreement with CareView ... with up to $40 million of secured debt financing. ... industry focused on patient care monitoring. Under ... to $40 million of debt financing in two tranches ...
(Date:6/29/2015)... NESS ZIONA, Israel , ... Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary ... M-001, BiondVax,s candidate for a universal influenza vaccine. In ... the ages of 50 to 65, followed by an ... 3 weeks later. M-001 was found to be safe ...
(Date:6/29/2015)... , June 29, 2015 DURECT ... James E. Brown , President and CEO, ... Conference on Wednesday, July 8 at 11:45 a.m. ... Le Parker Meridien Hotel in New York City.  ... may request a one-on-one meeting through the conference ...
Breaking Medicine Technology:PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3DURECT to Present at the Cantor Fitzgerald Healthcare Conference 2
... risk of,stroke by 34% in patient with atrial fibrillation or ... adequately treated by antithrombotic ... a,post-hoc analysis of the data from the ATHENA study were ... Society of Cardiology,congress 2008, in Munich, Germany. Previous results from ...
... in Subjects with ALS, RICHMOND, Calif., Sept. 3 ... that it has opened a Phase,2 clinical trial (SB-509-801) ... progressive, degenerative motor-neuron disease for which there,are limited treatment ... an injectable formulation of a plasmid,encoding a zinc finger ...
Cached Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5
(Date:6/30/2015)... ... 30, 2015 , ... Healthy and productive interpersonal relationships between ... According to Dr. Theo Wubbels (Professor of Education, Admissions Dean, Utrecht University), “Leadership ... “all kinds of behavior when the situation asks for it.” Wubbels, ...
(Date:6/30/2015)... ... June 30, 2015 , ... Medflow, the leader in ... electronic health records system from the company exclusively dedicated to helping eye care ... an intuitive state-of-the-art solution combining modern cloud technology with Medflow’s proven expertise in ...
(Date:6/30/2015)... ... ... This Fourth of July, Peacock Alley celebrates the American ideals ... perseverance, commitment to quality, honesty and love of friends and family. These are the ... love of quilts, Peacock Alley was fully realized and grown while raising her family. ...
(Date:6/30/2015)... ... , ... Curly Hair Solutions™ is honoured to attend Cosmoprof North America in ... products from all over the world. For the first time ever, Curly Hair Solutions™ ... styling products focused entirely on meeting the needs of all curl types ...
(Date:6/29/2015)... ... June 30, 2015 , ... The National Association ... inductee into its VIP Woman of the Year Circle. She is recognized with ... organization exclusively for professional women, boasting more than 700,000 members and over 200 ...
Breaking Medicine News(10 mins):Health News:Lessons On Leadership - Top 12 Global Teacher Bloggers Reveal the Best Strategies for Building Positive Leadership in Global Classrooms 2Health News:Medflow Launches MEDFLOW 2.0 EHR – The Cloud-Based Ophthalmology EHR 2Health News:Luxury Linen Purveyor Peacock Alley Celebrates the Fourth of July 2Health News:Curly Hair Solutions™ Showcases Entire Curl Keeper™ Collection at Cosmoprof Las Vegas July 12 - 14 2Health News:National Association of Professional Women Inducts Melanie Richards, DMD, of Powdersville Pediatric Dentistry, Into its VIP Woman of the Year Circle 2
... after four private companies took over the reins of the ... created huge problems for patients for whom oxygen supply can ... that about 60,000 people are in need of oxygen at ... deliveries of Oxygen have taken a beating. A woman reportedly ...
... pediatrics at the Medical College of Wisconsin said that adult ... ,Both have different levels of chemicals (enzymes) in their ... in concentration with age. ,Hence this study suggests ... the young. ,This plays a vital role because ...
... online in the International Journal of Cancer on February 17, ... colon cancer and the level of physical activity in women. ... found no such link. ,Experts felt that since ... insulin besides increasing the gastrointestinal transit time, it might also ...
... claimed the lives of at least 52 inhabitants of ... French National Health Agency (INVS). // ,The incurable ... people since the epidemic broke out in the Indian ... have contracted the disease over the past week, according ...
... Parents need to be more watchful when taking care of their ... revealed that they are more likely to suffer from burn injuries ... ,Researchers at Malmo University in Sweden looked at 148 children up ... Hospital and 21 health centres. They discovered that 96 percent of ...
... Birth under the Guangdong Family Planning Research Institute in ... discovered 39 cases of new abnormal chromosomes. // ... scientists for genetic and cloning researches. ,Director ... these cases of abnormal chromosomes have been verified by ...
Cached Medicine News:Health News:Women, Exercise and Colon Cancer 2
Inquire...
... three styles. Each style has multiple sizes. ... popular style. Pectoral Implants are available non-sterile ... individually, not in pairs. Both styles are ... for a specific side and are directional. ...
... In vivo results may be affected by the ... scar tissue can impact the desired augment-ation 1 ... from patient to patient. Implant dimensions can be ... surgical scissors. All dimensions in centimeters. This device ...
... IQmark family elevates your ECG and Spirometry capabilities ... and efficient patient care. The IQmark Diagnostic PDA ... clinics and medical centers as well as for ... conjunction with the IQmark Digital ECG PDA and ...
Medicine Products: